BridgeMD
The optimal timing of vaccination in pregnancy: a multi-dimensional mechanistic approach to measure immune responses in pregnant women (MATIMMUNE)
EU CTIS ID: 2024-518692-56-00
What this study is testing
To assess the impact of timing of pertussis vaccination in pregnancy on humoral and cellular immune responses in pregnant women, at delivery and postpartum.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Ability to provide informed consent.
- Willing to be vaccinated with a Tdap vaccine during pregnancy.
- Intend to be available for follow-up visits and phone call access until 6 months postpartum.
- Influenza and COVID-19 vaccination during pregnancy (as per Belgian recommendations) is allowed.
You likely can't join if
- Vaccinated with an aP containing vaccine during the last 5 years.
- Significant mental illness (e.g. schizophrenia, psychosis, major depression).
- Serious underlying immunological condition (e.g. immunosuppressive disease or therapy, human immunodeficiency virus (HIV) infection…).
- Systemic treatment with immune suppressive medication, including chronic steroid use of > 10 mg prednisone or equivalent.
- Anything in the opinion of the investigator that would prevent volunteers from completing the study or put the volunteer at risk.
- Previous severe reaction to any vaccine
See the full eligibility criteria
- Ability to provide informed consent.
- Willing to be vaccinated with a Tdap vaccine during pregnancy.
- Intend to be available for follow-up visits and phone call access until 6 months postpartum.
- Influenza and COVID-19 vaccination during pregnancy (as per Belgian recommendations) is allowed.
- Vaccinated with an aP containing vaccine during the last 5 years.
- Significant mental illness (e.g. schizophrenia, psychosis, major depression).
- Serious underlying immunological condition (e.g. immunosuppressive disease or therapy, human immunodeficiency virus (HIV) infection…).
- Systemic treatment with immune suppressive medication, including chronic steroid use of > 10 mg prednisone or equivalent.
- Anything in the opinion of the investigator that would prevent volunteers from completing the study or put the volunteer at risk.
- Previous severe reaction to any vaccine
- High risk for serious obstetrical complications.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.